What is HC Wainwright’s Forecast for TARS FY2026 Earnings?

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) – Research analysts at HC Wainwright lowered their FY2026 earnings per share (EPS) estimates for shares of Tarsus Pharmaceuticals in a note issued to investors on Wednesday, November 4th. HC Wainwright analyst M. Caufield now forecasts that the company will post earnings per share of ($15.85) for the year, down from their prior forecast of ($2.25). HC Wainwright has a “Buy” rating and a $106.00 price objective on the stock. The consensus estimate for Tarsus Pharmaceuticals’ current full-year earnings is ($2.23) per share. HC Wainwright also issued estimates for Tarsus Pharmaceuticals’ Q4 2026 earnings at ($0.55) EPS, FY2027 earnings at $1.37 EPS, FY2028 earnings at $3.65 EPS, FY2029 earnings at $5.97 EPS and FY2030 earnings at $8.49 EPS.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its earnings results on Tuesday, November 3rd. The company reported ($14.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.46) by ($12.94). Tarsus Pharmaceuticals had a negative net margin of 102.93% and a negative return on equity of 24.51%. The business had revenue of $194.57 million during the quarter, compared to analyst estimates of $187.83 million.

A number of other research analysts also recently commented on the stock. Guggenheim increased their price objective on shares of Tarsus Pharmaceuticals from $89.00 to $97.00 and gave the company a “buy” rating in a research note on Thursday. Weiss Ratings restated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research note on Thursday, October 15th. Barclays assumed coverage on shares of Tarsus Pharmaceuticals in a research report on Wednesday, September 16th. They set an “overweight” rating and a $110.00 price target on the stock. Oppenheimer lifted their price target on Tarsus Pharmaceuticals from $97.00 to $100.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 12th. Finally, Mizuho decreased their price target on Tarsus Pharmaceuticals from $100.00 to $98.00 and set an “outperform” rating for the company in a research note on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $104.57.

Tarsus Pharmaceuticals Stock Down 2.2%

Shares of NASDAQ:TARS opened at $67.52 on Friday. The firm has a market cap of $3.33 billion, a PE ratio of -4.45 and a beta of 0.34. The company has a fifty day simple moving average of $75.06 and a 200 day simple moving average of $67.83. The company has a current ratio of 1.96, a quick ratio of 3.17 and a debt-to-equity ratio of 0.70. Tarsus Pharmaceuticals has a 12-month low of $53.89 and a 12-month high of $91.53.

Insider Buying and Selling

In other Tarsus Pharmaceuticals news, Director William J. Phd Link sold 12,500 shares of the stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $78.38, for a total transaction of $979,750.00. Following the sale, the director directly owned 94,487 shares of the company’s stock, valued at approximately $7,405,891.06. This represents a 11.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Bobak R. Azamian sold 10,000 shares of the firm’s stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $90.56, for a total transaction of $905,600.00. Following the completion of the transaction, the chief executive officer owned 827,991 shares in the company, valued at approximately $74,982,864.96. The trade was a 1.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 48,031 shares of company stock worth $4,004,227 over the last ninety days. 9.64% of the stock is owned by insiders.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. Rockefeller Capital Management L.P. boosted its stake in Tarsus Pharmaceuticals by 15.5% during the 4th quarter. Rockefeller Capital Management L.P. now owns 1,283 shares of the company’s stock valued at $105,000 after purchasing an additional 172 shares during the period. Parallel Advisors LLC grew its position in Tarsus Pharmaceuticals by 139.2% in the 1st quarter. Parallel Advisors LLC now owns 500 shares of the company’s stock worth $35,000 after purchasing an additional 291 shares during the last quarter. Covestor Ltd grew its position in Tarsus Pharmaceuticals by 40.0% in the 3rd quarter. Covestor Ltd now owns 1,095 shares of the company’s stock worth $86,000 after purchasing an additional 313 shares during the last quarter. Strs Ohio grew its position in Tarsus Pharmaceuticals by 4.8% in the 1st quarter. Strs Ohio now owns 8,800 shares of the company’s stock worth $617,000 after purchasing an additional 400 shares during the last quarter. Finally, Eurizon Capital SGR S.p.A. acquired a new stake in shares of Tarsus Pharmaceuticals in the third quarter valued at approximately $35,000. Institutional investors and hedge funds own 90.01% of the company’s stock.

Key Tarsus Pharmaceuticals News

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Third-quarter revenue rose 63.9% to about $194.5 million, with record sales of XDEMVY. Tarsus expects $715 million–$730 million in XDEMVY sales for 2026, supporting the growth outlook. Article: Tarsus expects $715M-$730M 2026 XDEMVY sales
• Positive Sentiment: Analysts raised price targets and maintained bullish ratings: Guggenheim lifted its target to $97 with a Buy rating, while Oppenheimer raised its target to $103 and kept an Outperform rating. Guggenheim rating Oppenheimer price target
• Neutral Sentiment: Management plans to participate in upcoming investor conferences; this may provide opportunities to discuss the business and outlook, but no new financial information was announced. Tarsus investor conference announcement
• Negative Sentiment: The quarterly net loss widened to $668 million, primarily due to acquisition-related costs, despite revenue growth. Tarsus also deferred European and Japanese filing plans, delaying potential international expansion. Q3 loss and XDEMVY sales Sales outlook and international filing plans

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a commercial-stage ophthalmic pharmaceutical company focused on developing and marketing treatments for eye diseases with significant unmet medical needs. The company’s portfolio is centered on therapies designed to address conditions affecting the ocular surface and eyelids.

Tarsus’ lead product is XDEMVY (lotilaner ophthalmic solution) 0.25%, an eye drop approved by the U.S. Food and Drug Administration in 2023 for the treatment of Demodex blepharitis, an inflammatory eyelid condition associated with an infestation of Demodex mites.